Press Releases

Excipients in Pharmaceutical Market to Reach $8.7 billion in 2022

May 01, 2018

Additional Reports

WELLESLEY, Mass., May 01, 2018 – Growing demand for medicinal products, innovation in drug delivery systems, along with numerous mergers and acquisitions are helping to drive the global pharmaceutical excipients market forward, according to a report by BCC Research.

The industry is expected to reach a compound annual growth rate (CAGR) of 4.9% through 2022, when it could be worth $8.7 billion, according to the report Excipients in Pharmaceuticals: Global Markets to 2022.

Excipients are initially inactive until they are added to an active ingredient, and are capable of producing a finished pharmaceutical product.

Major players in the market include Ashland Global Holdings Inc., BASF, Cargill Inc., The Dow Chemical Co., Meggle Pharma, Merck & Co., Omya and Roquette Freres.

Research Highlights

  • Currently, the market is fragmented with a large number of players offering disparate products. However, with the merger of Dow and DuPont in August 2017, the market could be ripe for further consolidation. DuPont also acquired FMC Corporation’s excipient business in March 2017.
  • North America will lead the market by size, with a 2022 value estimated at $427.1 million. Meanwhile, the Asia-Pacific region will lead the industry by growth, with a projected CAGR through 2022 of 7.3%.
  • Excipients derived from natural sources will remain the prime focus of attention for manufacturers as inorganic excipients are likely to face decline.

“One of the most important drivers for the excipient industry is the global demand for pharmaceutical products,” the report notes. “Although the blockbuster model of the pharmaceutical industry is almost obsolete, the demand for novel drugs for orphan and new emerging diseases is driving research and development of drugs. Further, with many of the existing drugs that are witnessing patent cliffs and are being replaced by increased availability of generics, the demand for discounted generic versions of the drugs is increasing globally.”

Market Challenged by Supply Chain Disruption, Quality Standards Maintenance

The pharmaceutical industry production process is long and complex, and an efficient supply chain is needed to keep it functioning smoothly. Import restrictions that are currently underway in the United States could disrupt the global supply chain. Meanwhile, quality standards are difficult to meet and required audits pose a significant limitation as manufacturers seek to build synergy between pharmaceutical and excipient manufacturers.

Editors/reporters requesting analyst interviews should contact steven.cumming@bccresearch.com.

Excipients in Pharmaceuticals: Global Markets to 2022( PHM010K )
Publish Date: Apr 2018    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC, 49 Walnut Park, Building 2, Wellesley, MA 02481, Telephone: 866-285-7215; Email: editorial@bccresearch.com as the source and publisher. Thank you.